评估桡动脉-头静脉动静脉内瘘建立后重复干预的国家指南一致性
本研究基于多中心PATENCY-1和PATENCY-2随机试验的前瞻性数据,分析914例新建桡动脉-头静脉动静脉内瘘患者。术后1年干预发生率为1.04次/人年(95%CI 0.95-1.13),与KDOQI指南目标一致;女性、糖尿病、术中静脉直径<3.0 mm及已透析患者干预风险更高,但无亚组超过指南建议的干预上限。
要点
- 桡动脉-头静脉内瘘术后1年干预率为1.04次/人年,符合KDOQI指南基准。
- 女性、糖尿病、术中静脉直径<3.0 mm及已透析者干预更早更频繁。
- 最常见干预为球囊血管成形术(占54.9%),其次为静脉侧支结扎和开放翻修(各16.4%)。
核心结论
- 桡动脉-头静脉动静脉内瘘患者术后第一年平均接受一次干预,与当前KDOQI指南一致。
- 已需血液透析、女性、糖尿病及术中静脉直径<3.0 mm的患者重复干预风险增加。
- 无亚组超过指南建议的重复干预最大阈值。
- 在适当选择的患者中,作为终末期肾病生命规划的一部分,创建桡动脉-头静脉动静脉内瘘仍是符合指南的策略。
研究设计与样本
- 描述性研究,分析多中心PATENCY-1和PATENCY-2随机试验的前瞻性患者层面数据(ClinicalTrials.gov NCT02110901和NCT02414841)。
- 纳入914例接受新桡动脉-头静脉动静脉内瘘创建的患者;平均年龄57岁(标准差13岁),22%为女性。
- 中位随访707天(四分位距447-1066天)。
主要发现
- 总体干预发生率为1.04次/人年(95%CI 0.95-1.13);内瘘使用前为1.10次/人年(95%CI 0.98-1.21),使用后为0.96次/人年(95%CI 0.82-1.11)。
- 最常见干预为球囊血管成形术(占所有干预的54.9%)、静脉侧支结扎(16.4%)和开放翻修(如从鼻烟壶至腕部的近端化,16.4%)。
- 需球囊血管成形术的部位包括吻合口近端段(占成形术的51.7%)、流出静脉(29.2%)、流入动脉(14.8%)、中心静脉(3.8%)和头静脉弓(0.5%)。
- 常见指征为恢复或维持通畅(占所有干预的75.6%)、辅助成熟(14.9%)、改善深度(4.4%)或改善增强(3.0%)。
- 多变量回归分析中,女性(校正HR 1.21;95%CI 1.05-1.45)、糖尿病(HR 1.21;95%CI 1.01-1.46)和术中静脉直径<3.0 mm(对比≥4.0 mm:HR 1.33;95%CI 1.02-1.66)与更早更频繁的干预相关;内瘘创建时未行血液透析的患者干预频率较低(HR 0.69;95%CI 0.59-0.81)。
关键数值与推荐
- KDOQI指南强调以患者为中心的血液透析通路策略,并设定了新的干预率最大目标。
- 本队列总体干预率为1.04次/人年(95%CI 0.95-1.13),无亚组超过指南建议的重复干预最大阈值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Radiocephalic arteriovenous fistulas have been historically perceived as requiring multiple follow-up procedural interventions to achieve maturation and maintain patency. Recent clinical practice guidelines from the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDOQI) emphasize a patient-centered hemodialysis access strategy with new maximum targets for intervention rates, potentially conflicting with concomitant recommendations to prioritize autogenous forearm hemodialysis access creation. The present descriptive study seeks to assess whether radiocephalic fistulas can meet the KDOQI guideline benchmarks for interventions following access creation, and to elucidate clinical and anatomic characteristics associated with the timing and frequency of interventions following radiocephalic arteriovenous fistula creation. METHODS: Prospective patient-level data from the multicenter PATENCY-1 and PATENCY-2 randomized trials, which enrolled patients undergoing new radiocephalic arteriovenous fistula creation, was analyzed (ClinicalTrials.govNCT02110901 and NCT02414841). The primary outcome was the rate of interventions at 1 year postoperatively. Incidence rates were calculated, and time to surgical or endovascular intervention following fistula creation was modeled using recurrent event extensions of the Cox proportional hazards model. Confidence intervals at the 95% level were calculated using nonparametric bootstrapping. RESULTS: The cohort consisted of 914 patients; mean age was 57 years (standard deviation, 13 years), and 22% were female. Median follow-up was 707 days (interquartile range, 447-1066 days). The incidence of interventions per person-year was 1.04 (95% confidence interval [CI], 0.95-1.13) overall; 1.10 (95% CI, 0.98-1.21) before fistula use, and 0.96 (95% CI, 0.82-1.11) after fistula use. The most common interventions overall were balloon angioplasty (54.9% of all interventions), venous side-branch ligation (16.4%), and open revisions (eg, proximalization from snuffbox to wrist, 16.4%). The locations requiring balloon angioplasty included the juxta-anastomotic segment (51.7% of angioplasties), the outflow vein (29.2%), the inflow artery (14.8%), the central veins (3.8%), and the cephalic arch (0.5%). Common indications were to restore or maintain patency (75.6% of all interventions), assist maturation (14.9%), improve depth (4.4%), or improve augmentation (3.0%). In the multivariable regression analysis, female sex (adjusted hazard ratio [HR], 1.21; 95% CI, 1.05-1.45), diabetes (HR, 1.21; 95% CI, 1.01-1.46), and intraoperative vein diameter <3.0 mm (vs ≥4.0 mm: HR, 1.33; 95% CI, 1.02-1.66) were associated with earlier and more frequent interventions. Patients not on hemodialysis at the time of fistula creation underwent less frequent interventions (HR, 0.69; 95% CI, 0.59-0.81). CONCLUSIONS: Patients with radiocephalic arteriovenous fistulas can expect to undergo one intervention, on average, in the first year after creation, which aligns with current KDOQI guidelines. Patients already requiring hemodialysis, female patients, patients with diabetes, and patients with intraoperative vein diameters <3.0 mm were at increased risk for repeated intervention. No subgroup exceeded guideline-suggested maximum thresholds for recurrent interventions. Overall, the results demonstrate that creation of radiocephalic arteriovenous fistula remains a guideline-concordant strategy when part of an end-stage kidney disease life-plan in appropriately selected patients.
引用
- Heindel P, Fitzgibbon JJ, Feliz JD, et al. Evaluating national guideline concordance of recurrent interventions after radiocephalic arteriovenous fistula creation. J Vasc Surg. 2022. PMID: 36567000. doi:10.1016/j.jvs.2022.12.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。